Markets finish week down after bouncing on Bannon's exit >>> READ MORE

10 Best S&P 500 Stocks of Q1

Some of 2012's big stinkers are huge winners thus far in 2013

      View All  

#9: Celgene

Celgene185YTD Performance: +44%

Celgene (NASDAQ:CELG) is a biopharmaceutical company that focuses on niche drugs serving cancer and immune diseases. While the patient pools can be smaller, the treatments also can be very high-margin products and thus make up for reach with profitability.

Celgene kicked off 2012 with serious buzz thanks to impressive reviews at a JPMorgan healthcare conference that resulted in a slew of upgrades from top Wall Street firms. However, some investors are worried that CELG stock has all the profits already baked in.

Still, the long-term potential of its cancer cures and drug pipeline might give you reason to consider a position.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC